Buscar en
Clínica e Investigación en Arteriosclerosis (English Edition)
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis (English Edition) Progressive cardiovascular disease in a patient under treatment with nilotinib
Journal Information
Vol. 32. Issue 2.
Pages 66-69 (March - April 2020)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 32. Issue 2.
Pages 66-69 (March - April 2020)
Case Report
Progressive cardiovascular disease in a patient under treatment with nilotinib
Enfermedad cardiovascular progresiva en paciente bajo tratamiento con nilotinib
Visits
...
Ricardo Roa-Chamorroa,
Corresponding author
ricardoroa@gmail.com

Corresponding author.
, Lucía Torres-Quinterob, Carlos García de los Ríosa, José Manuel Puerta-Puertac, Pablo González-Bustosa, Juan Diego Mediavilla-Garcíaa
a Unidad de Riesgo Vascular, Medicina Interna, Hospital Universitario Virgen de las Nieves, Granada, Spain
b Servicio de Cardiología, Hospital Universitario Virgen de las Nieves, Granada, Spain
c Servicio de Hematología y Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. The most frequent cardiovascular effects of TKI.
Abstract

The development of cardiovascular disease (CVD) appears in subjects with several cardiovascular risk factors (CVRF). However, other agents could be related to the appearance of CVD, like chemotherapy drugs. We present a 63 years-old man with very high cardiovascular risk (CVR) and chronic myeloid leukemia under treatment with nilotinib. Despite a good control of cardiovascular risk factors, he development a severe and acceleratted peripherical arterial disease (PAD). PAD occurs in 5–20% patients under treatment with nilotinib and it is more frecuently in subjects with several CVRF.

Keywords:
Chronic myeloid leukaemia
Nilotinib
Peripheral arterial disease
Resumen

El desarrollo de enfermedad cardiovascular (ECV) suele presentarse en sujetos con varios factores de riesgo cardiovascular (FRCV). Sin embargo, existen otros condicionantes que pueden estar relacionados con la aparición de ECV, como pueden ser los fármacos antineoplásicos. Presentamos en caso de un varón de 63 años con muy alto riesgo cardiovascular (RCV), con antecedente personal de leucemia mieloide crónica (LMC) en tratamiento con nilotinib que, a pesar de buen control metabólico, desarrolló una enfermedad arterial periférica (EAP) grave y acelerada. La EAP se ha descrito en el 5-20% de los pacientes bajo tratamiento con nilotinib, siendo más frecuentes en los sujetos con varios FRCV.

Palabras clave:
Leucemia mieloide crónica
Nilotinib
Enfermedad arterial periférica

Article

These are the options to access the full texts of the publication Clínica e Investigación en Arteriosclerosis (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Clínica e Investigación en Arteriosclerosis (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos